{"analyses":[{"ciLowerLimit":"0.77","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.07","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"1.27"},{"ciLowerLimit":"0.74","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.96","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"1.20"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"92.3","upperLimit":"99.2","value":"97.4"},{"groupId":"OG001","lowerLimit":"91.0","upperLimit":"98.4","value":"96.2"},{"groupId":"OG002","lowerLimit":"94.2","upperLimit":"99.9","value":"99.2"}]}],"title":"Week 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"90.0","upperLimit":"98.2","value":"95.7"},{"groupId":"OG001","lowerLimit":"90.0","upperLimit":"97.9","value":"95.4"},{"groupId":"OG002","lowerLimit":"92.4","upperLimit":"99.2","value":"97.5"}]}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"60.9","upperLimit":"77.5","value":"70.1"},{"groupId":"OG001","lowerLimit":"62.9","upperLimit":"78.5","value":"71.5"},{"groupId":"OG002","lowerLimit":"66.9","upperLimit":"82.4","value":"75.6"}]}],"title":"Week 18"}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"130"},{"groupId":"OG002","value":"119"}],"units":"Participants"}],"description":"Comparison of time to treatment discontinuation in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during the core phase. Treatment duration is defined as the time from randomization until the date of permanent study treatment discontinuation (for any reason) at any time during the Core phase.\n\nThe percentage event-free probability estimate is the estimated probability that a patient will remain on-treatment up to a specified time point (Week 6, 12, 18)","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were randomized to receive everolimus dispersible tablets for oral suspension with titration to a low trough (LT) range of 3 to 7 ng/mL","id":"OG000","title":"Everolimus LT Target of 3 to 7 ng/mL"},{"description":"Participants were randomized to receive everolimus dispersible tablets for oral suspension with titration to a high trough (HT) range of 9 to 15 ng/mL","id":"OG001","title":"Everolimus HT Target of 9 to 15 ng/mL"},{"description":"Participants were randomized to receive placebo dispersible tablets for oral suspension.","id":"OG002","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"The Full Analysis Set (FAS) comprised all patients to whom study treatment was assigned by randomization","reportingStatus":"POSTED","timeFrame":"Week 6, Week 12, Week 18","title":"Core Phase: Probability That a Patient Remains On-treatment up to a Specified Time Point","type":"SECONDARY","unitOfMeasure":"Percentage event-free prob. estimates"}